📰 Anders Ullman News

Page 2 - Anders Ullman News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Anders Ullman. Real-time updates on events, politics, business and more.

Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum AB

March 2, 2023

/PRNewswire/ -- Sobi® and Sanofi today announced that the XTEND-Kids phase 3 pivotal study evaluating the safety, efficacy and pharmacokinetics of...

United States Anders Ullman Thomas Kudsk Larsen Prnewswire Sobi Sobi Investor Relations Team Amunix Pharmaceuticals Inc

Source: prnewswire.com

FDA approves once-weekly efanesoctocog alfa, a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum AB

February 24, 2023

/PRNewswire/ -- Sobi® today announced that the US Food and Drug Administration (FDA) has approved efanesoctocog alfa [Antihemophilic Factor (Recombinant),...

United States Lynn Malec Anders Ullman European Commission Drug Administration Sobi Investor Relations Team

Source: prnewswire.com

Changes to Sobi's management

February 2, 2023

/PRNewswire/ -- Anton (Tony) Hoos, M.D., Ph.D., MBA will become Head of R&D and Medical Affairs and Chief Medical Officer and replace Anders Ullman, M.D., Ph.D....

United States North Carolina Anton Tony Hoos Anders Ullman Tony Hoos Guido Oelkers

Source: prnewswire.com

NEJM publishes data demonstrating clinically meaningful prevention of bleeds and superior bleed protection for efanesoctocog alfa

January 26, 2023

/PRNewswire/ -- Pivotal study data published in The New England Journal of Medicine (NEJM) continues to highlight the efficacy, safety, and pharmacokinetic...

United States Anders Ullman European Commission Us Food Drug Administration Sobi Investor Relations Team Head Of Research Development

Source: prnewswire.com

EC approves Zynlonta® for large B-cell lymphoma

December 23, 2022

Antibody drug conjugate Zynlonta can now be used in all European Union member states, Iceland, Norway and Liechtenstein.

Anders Ullman European Union European Commission Drug Administration Head Of Research Development European Medicines Agency

Source: europeanpharmaceuticalreview.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

EC approves Sobi-ADC's Zynlonta for diffuse large B-cell lymphoma

December 22, 2022

The EC has granted conditional marketing authorisation for Sobi and ADC Therapeutics’ Zynlonta to treat diffuse large B-cell lymphoma.

Anders Ullman Sobi Research Development Committee For Medicinal Products Human European Union European Medicines Agency European Commission

Source: pharmaceutical-technology.com

Swedish Orphan Biovitrum AB: Zynlonta (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma

December 21, 2022

STOCKHOLM, Dec. 21, 2022 /PRNewswire/ -- Sobi and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of Zynlonta

United States New Jersey United Kingdom City Of Lausanne Biop Anders Ullman

Source: finanznachrichten.de

Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell l

December 21, 2022

STOCKHOLM, Dec. 21, 2022 /PRNewswire/ -- Sobi® and ADC Therapeutics SA today announced that the European...

United States New Jersey City Of United Kingdom Lausanne Biop Anders Ullman

Source: europapress.es

Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma

December 21, 2022

/PRNewswire/ -- Sobi® and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of...

United States New Jersey United Kingdom City Of Lausanne Biop Anders Ullman

Source: prnewswire.com